Positive business performance in first quarter – Confident outlook for 2024 – Biotech Investments

Asklepios Group: Positive business performance in first quarter – Confident outlook for 2024

• Consolidated revenue up year-on-year at EUR 1,414.5 million
• Consolidated net income (EAT) of EUR 18.5 million
• Increase in patient and employee numbers

Hamburg, 23 May 2024. Asklepios Kliniken GmbH & Co. KGaA has enjoyed a solid economic performance in the first three months of the 2024 financial year. The Asklepios Group can report a positive development despite the ongoing uncertainty in the healthcare sector and global economic challenges.

Asklepios has further consolidated its role as a reliable healthcare partner: 919,532 patients in total were treated in the Asklepios Group’s healthcare facilities in the first three months of the 2024 financial year (3M 2023: 860,826). The number of inpatients was 196,297, 1.9% higher than in the previous year (3M 2023: 192,731), while the number of outpatients rose by 8.3% to 723,235 (3M 2023: 668,095).

Asklepios employed 50,272 full-time equivalents on average in the period from January to March (3M 2023: 49,393). This increase is as a result of strategic recruitment activities and the successful hiring of skilled workers from Germany and abroad.

Revenue increased by 5.4% year-on-year to EUR 1,414.5 million in the first quarter of 2024 (3M 2023: EUR 1,341.8 million). Staff costs rose by EUR 49.6 million as against the same period of the previous year to EUR 974.5 million as a result of pay increases and the growth in headcount. The staff costs ratio matched the previous year’s level at 68.9% (3M 2023: 68.9%). Consolidated net income (EAT) grew to EUR 18.5 million (3M 2023: EUR 9.2 million).

Marco Walker, CEO of Asklepios Kliniken, commented: “The satisfactory development in the first quarter of 2024 is a clear sign that we are well positioned despite the challenging situation in the German healthcare sector. Our long-term business strategy and the tireless efforts of our employees give us cause to be confident in our outlook for the remainder of the financial year.”

Joachim Gemmel, CEO of Asklepios Kliniken, said: “Our economic stability allows us to look forward with confidence to the far-reaching changes in the healthcare sector. At the same time, we are calling on politicians to create reliable and stable solutions for good healthcare with the upcoming hospital reform.”

Investments including subsidies amounted to EUR 67.4 million. (3M°2023: EUR 77.4 million).

Hafid Rifi, CFO of Asklepios Kliniken, said: “We are operating on a solid basis and are now setting the right course to further consolidate and expand our market position. Moving forward, we will continue to rely on a stable capital structure and long-term financing strategies.”

On the basis of its size and structure, the Asklepios Group is robustly positioned and can respond flexibly to changes, even in a volatile market environment. The upcoming hospital reform will define the 2024 financial year and shape the Group’s performance. In this context, Asklepios is continuing to campaign for the government to take swift and effective action to relieve the pressure on hospitals. The Group’s stated aim for the financial year is still to continuously increase its operating result and thus achieve greater economic flexibility for the expansion of first-class healthcare in Germany.

 About Asklepios

Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has developed dynamically since it was founded more than 35 years ago. The Group now has more than 164 healthcare facilities across Germany, including acute care hospitals for all levels of care, university hospitals, specialist clinics, psychiatric and forensic facilities, rehabilitation clinics, nursing homes and medical centres. More than 3.5 million patients were treated at the Asklepios Group’s facilities in the 2023 financial year. The company has more than 68,000 employees.

IR contact
Mirjam Constantin
Head of Corporate & ESG Reporting / Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 – 61462 Königstein-Falkenstein
Phone: +49 61 74 90-1166
ir@asklepios.com

PR contact
Rune Hoffmann
Head of Corporate Communication & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 – 22307 Hamburg
Phone: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639 
presse@asklepios.com

Visit Asklepios online, on Facebook or on YouTube
www.asklepios.com
gesundleben.asklepios.com
www.facebook.com/asklepioskliniken
www.youtube.com/asklepioskliniken

Subscribe to the Asklepios newsletter
https://www.asklepios.com/konzern/newsletter-anmeldung/
Nursing blog: “Wir sind Pflege”